middle.news
How Starpharma Is Unlocking Value in Its DEP® Pipeline Amid Global Expansion
10:10am on Thursday 31st of July, 2025 AEST
•
Biotechnology
Read Story
How Starpharma Is Unlocking Value in Its DEP® Pipeline Amid Global Expansion
10:10am on Thursday 31st of July, 2025 AEST
Key Points
165% increase in underlying customer receipts for FY25
Progress on out-licensing clinical-stage DEP® assets despite extended timelines
Preclinical advancement of DEP® radiotheranostics program
New distribution agreements for VivaGel® BV and Viraleze™ in Asia and Saudi Arabia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma Holdings (ASX:SPL)
OPEN ARTICLE